Coloplast A Stock Performance
| CLPBY Stock | USD 12.58 0.07 0.56% |
The firm shows a Beta (market volatility) of 0.35, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Coloplast's returns are expected to increase less than the market. However, during the bear market, the loss of holding Coloplast is expected to be smaller as well. At this point, Coloplast A has a negative expected return of -0.14%. Please make sure to confirm Coloplast's value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Coloplast A performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Coloplast A has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 448 M | |
| Total Cashflows From Investing Activities | -11.8 B |
Coloplast |
Coloplast Relative Risk vs. Return Landscape
If you would invest 1,388 in Coloplast A on August 27, 2024 and sell it today you would lose (130.00) from holding Coloplast A or give up 9.37% of portfolio value over 90 days. Coloplast A is currently producing negative expected returns and takes up 1.416% volatility of returns over 90 trading days. Put another way, 12% of traded pink sheets are less volatile than Coloplast, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Coloplast Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coloplast's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Coloplast A, and traders can use it to determine the average amount a Coloplast's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1015
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLPBY |
Estimated Market Risk
| 1.42 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Coloplast is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Coloplast by adding Coloplast to a well-diversified portfolio.
Coloplast Fundamentals Growth
Coloplast Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Coloplast, and Coloplast fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Coloplast Pink Sheet performance.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 28.84 B | |||
| Shares Outstanding | 2.12 B | |||
| Price To Earning | 37.95 X | |||
| Price To Book | 22.46 X | |||
| Price To Sales | 1.13 X | |||
| Revenue | 22.58 B | |||
| EBITDA | 7.23 B | |||
| Cash And Equivalents | 854 M | |||
| Cash Per Share | 0.40 X | |||
| Total Debt | 16.36 B | |||
| Debt To Equity | 2.83 % | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | 5.1 B | |||
| Earnings Per Share | 0.31 X | |||
| Total Asset | 34.96 B | |||
About Coloplast Performance
Evaluating Coloplast's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Coloplast has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Coloplast has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast is traded on OTC Exchange in the United States.Things to note about Coloplast A performance evaluation
Checking the ongoing alerts about Coloplast for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Coloplast A help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Coloplast A generated a negative expected return over the last 90 days |
- Analyzing Coloplast's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Coloplast's stock is overvalued or undervalued compared to its peers.
- Examining Coloplast's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Coloplast's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Coloplast's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Coloplast's pink sheet. These opinions can provide insight into Coloplast's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Coloplast Pink Sheet Analysis
When running Coloplast's price analysis, check to measure Coloplast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coloplast is operating at the current time. Most of Coloplast's value examination focuses on studying past and present price action to predict the probability of Coloplast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coloplast's price. Additionally, you may evaluate how the addition of Coloplast to your portfolios can decrease your overall portfolio volatility.